Skip to main content
Log in

Bismuth-related acute neurotoxicity as stroke mimic: a case report

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Vilela P (2017) Acute stroke differential diagnosis: stroke mimics. Eur J Radiol 96:133–144

    Article  PubMed  Google Scholar 

  2. De Boer WA (2001) A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule. Expert Opin Investig Drugs 10:1559–1566

    Article  PubMed  Google Scholar 

  3. Gensini GF, Carolei A, Zaninelli A et al. SPREAD-Stroke Prevention and Educational Awareness Diffusion. Ictus cerebrale: Linee guida italiane di prevenzione e trattamento. In: ISO-spread [online] Available at: www.iso-spread.it. Accessed July 21, 2016

  4. Treiber G, Walker S, Klotz U (1994) Omeprazole-induced increase in the absorption of bismuth from tripotassium di-citrato bismuthate. Clin Pharmacol Ther 55(5):486–491

    Article  CAS  PubMed  Google Scholar 

  5. Nwokolo CU, Prewett EJ, Sawyerr AM, Hudson M, Pounder RE (1991) The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology 101:889–894

    Article  CAS  PubMed  Google Scholar 

  6. Yifan H, Yau-Tsz L, Godfrey C-FC, Hongzhe S (2015) Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells. PNAS [serial online] 112(11):3211–3216 Available at: www.pnas.org. Accessed March 17, 2015

    Google Scholar 

  7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245

    Article  CAS  PubMed  Google Scholar 

  8. U.S. Food and Drug Administration (2007). Pylera ™ Capsules (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) 140 mg/125 mg/125 mg. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050786 s001lbl.pdf. Accessed 18 October 2018

Download references

Author information

Authors and Affiliations

Authors

Contributions

Amelia Brigandì: study concept and design, acquisition of data, analysis and interpretation, and critical revision of the manuscript for important intellectual content.

Paolo Girlanda: acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content, and study supervision.

Vincenzo Rizzo: study concept and design, acquisition of data, analysis and interpretation, and critical revision of the manuscript for important intellectual content.

Vanessa Ziccone: acquisition of data and analysis and interpretation.

Corresponding author

Correspondence to Amelia Brigandì.

Ethics declarations

This article does not contain any studies with human participants performed by any of the authors.

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brigandì, A., Rizzo, V., Ziccone, V. et al. Bismuth-related acute neurotoxicity as stroke mimic: a case report. Neurol Sci 40, 653–654 (2019). https://doi.org/10.1007/s10072-018-3634-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-018-3634-5

Navigation